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ABSTRACT 
Objective: This study aims to investigate the ameliorative role of dietary bee honey and royal jelly against cisplatin-induced alterations in 
hematological parameters in male wistar albino rat.  
Methods: Male wistar albino rats of same age and weight were randomly divided into four groups; G, I: control group which was given 0.9% saline, 
G: II: cisplatin (7 mg/kg/d) was injected intraperitoneally for 15 d, G, III bee honey with royal jelly (500 mg/kg/d of honey and 100 mg/kg/d of 
royal jelly) fed orally daily for 15 d, G, IV: cisplatin (7 mg/kg/d) was injected intraperitoneally and honey (500 mg/kg/d) and royal Jelly (100 
mg/kg/d) fed orally daily for 15 d. The hematological parameters like total number of white blood cells (WBCs), red blood cells (RBCs), platelets, % 
of hemoglobin (Hb), and mean values of packed cell volume (PCV), mean corpuscular volume (MCV) and mean corpuscular hemoglobin 
concentration (MCHC) were measured by using automated hematology system. 
Results: Cisplatin treated rats revealed a significant decrease in total number of white blood cells (WBCs), red blood cells (R. B. Cs), platelets, percentage of 
hemoglobin (Hb), and mean values of packed cell volume (PCV), corpuscular volume (MCV) and corpuscular hemoglobin concentration (MCHC) as compared 
to control group. Royal jelly and honey treated group of rats revealed a significant increase in all blood parameters compared to control group. Dietary bee 
honey with royal jelly along with cisplatin-treated rats revealed significant increas as compared to animals treated with cisplatin (G, II) and the computed 
significant valus for the above parameters are 10.00, 2.30, 8,54, 12.00, 35.00, 47.40 and 32,30 respectively.  
Conclusion: Bee honey and royal jelly could be used as dietary preventive natural products against cisplatin-induced hematological alterations 
during the treatment of cancer. 
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Cisplatin is one of the most cytotoxic agents and is widely used to treat a 
variety of cancers, but it is associated with toxic side effects. The 
oxidative stress through the formation of free radicals is one of the 
mechanisms of cisplatin-induced toxicity [1]. The free radical scavengers, 
or which prevent the formation of the reactive hydroxyl free radicals, can 
provide protection against cisplatin-induced hematotoxicity, especially 
blood parameters [2]. Different natural products and dietary compounds 
have been recently investigated and evaluated as potential protective 
antioxidant agents against cisplatin-induced toxicity [3]. Honey and royal 
jelly are natural dietary substances, which previously tested to 
ameliorate the toxic side effects of a different substance, through their 
antioxidant, radical scavenging and antiperoxidative activity [4, 5].  
Blood delivers requisite materials such as nutrients and oxygen and 
carri away the waste products from the cells. It contains RBCs, WBCs 
and platelets, which are suspended in a fluid medium; plasma [6, 7]. 
The measurement of hematological parameters erythrocytes, 
leukocytes, platelets and concentration of hemoglobin are some of 
the most frequently performed clinical laboratory tests in which 
variations in the count of blood cells signal regarding diseases or ill 
health of human body. For overall health assessment and diagnosis 
of many disorders, complete blood count is required.  
Consequently, the aim of the present study was to investigate the 
ameliorative role of dietary bee honey and royal jelly against 
cisplatin-induced alterations in hematological parameters in male 
wistar albino rat. 
MATERIALS AND METHODS  
Animals 
Healthy male wistar albino rats weighing 200-250 gm (10-12 w age) 
were obtained from the animal house of R. C. Patel Institute of 
Pharmaceutical Education and Research, Shirpur-India. All the 
experimental procedures were carried out in accordance with the 
guidelines of the committee for the purpose of control and 
supervision of experiments on the animal (CPCSEA). All animal 
experiments were approved by the Institutional Animal Ethics 
Committee (IAEC) of RCPIPER, Shirpur (Reg No.-651/PO/ReBi/ 
S/02/CPCSEA). 
Housing conditions 
The rats were housed in standard plastic cages. The bedding 
material of the cages was changed every day. Maximum of 3 rats 
housed per polypropylene cage having a size of 32 X 11 cm with 
stainless steel grill top mesh having facility for holding food palate 
and a water bottle. The rats were allowed free access to food, diet 
and water throughout the experimental period. All animals were 
housed in an air-conditioned room at a temperature range between 
22-25 °C, relative humidity in between 30%-60% and with a 12-
hour light-dark cycle.  
Acclimatization 
Selected rats were randomly divided into four groups containing 6 
rats in each group and were allowed to acclimatize to laboratory 
conditions for 7 d prior to experimentation.  
Water 
Water processed by reverse osmosis and Ultraviolet (UV) light was 
supplied ad libitum to the rats. 
Chemicals 
Cisplatin was purchased from (Cipla Ltd company-Goa-India). Bee 
honey and royal jelly collected directly from the Apis mellifera 
colonies located in the university campus. Food pallet was 
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purchased from Nutrivet Life sciences, Pune, Maharashtra, India. All 
other chemicals used in the experiment were of analytical grade. 
Preparation of royal jelly and honey 
500 mg/kg/d of honey and 100 mg/kg/d of royal jelly were 
dissolved in distilled water and administered through an intragastric 
tube through the mouth. The doses were weighed on digital scales, 
where the dose relies on animal weight, in which every single gram 
of the experimental rat should receive 0.5 mg of honey and 0.1 mg of 
royal jelly.  
Experimental design  
For the study, 24 adult male wister albino rats of 10-12 w age and 
with 200-250g weight randomly divided into 4 groups; each group 
consisting of 6 rats and were treated for 15 d as below:  
Group I (Control): 0.9% (10 ml/kg/d) saline solution was 
administrated for 15 d. 
Group II (Cisplatin): Cisplatin (7 mg/kg/d) intraperitoneal injection 
for 15 d [8, 9]. 
Group III (bee honey+royal jelly): Bee honey (500 
mg/kg/d)+Royal jelly (100 mg/kg/d) orally administrated for 15 d 
[8, 10]. 
Group IV (Cisplatin+bee honey+royal jelly): 7 mg/kg/d of 
cisplatin intraperitoneal injection along with 500 mg/kg/d of 
honey+100 mg/kg/d of royal jelly orally were through an 
intragastric tube for 15 d. 
Blood collection: After 15 d of treatment, blood samples were 
collected via retro-orbital puncture under light ether anesthesia. 
Blood collected was put in tubes, containing a substance of 
Ethylenediaminetetraacetic acid (EDTA) (15-20 IU per ml of blood), 
to check the number of WBC, RBC, PLT, PCV, Hb, MCV, MCH and 
MCHC [11]. 
Hematological assay 
The hematological parameters like a total number of WBCs, RBCs, 
platelets, % hemoglobin (Hb), and mean values MCV, MCH and 
MCHC were measured by using automated Hematology System, 
Sysmex Exigo, Box 42056, SE-126 13 Stockholm, Sweden. 
Statistical analysis 
All data were expressed as mean±S. E. M and statistically analyzed 
using Graph Pad Prism 7 for Windows (Prism Inc, Chicago, IL, U. S. 
A). The statistical significance of differences among different study 
groups was evaluated by one-way analysis of variance (ANOVA) 
followed by Bonferroni’s multiple comparison tests as a post hoc 
test. P value of 0.05 or less was taken as a criterion for a statistically 
significant difference. 
RESULTS 
Effect of treatment of cisplatin (G, II), bee honey and royal jelly (G, 
III), and the combined treatment of cisplatin with bee honey and 
royal jelly (G, IV) on hematological parameters of male wistar albino 
rats were evaluated in comparison with control group (G, I) for the 
period of 15 d and obtained results were summarized in (table 1). 
The results demonstrated that cisplatin treated rats, (G, II), exhibited 
significant decrease in the total number of white blood cells (WBC), 
red blood cells (RBC), platelets (PLT), hemoglobin% (Hb) and mean 
values of packed cell volume (PCV), mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH) contents and the 
percentages decreased was 22.7%, 55.5%, 36.25%, 14.9%, 34.1%, 
19.3% and 24.9%, respectively as compared to the control group 
rats.  
In the present study, it was observed that after honey and royal jelly 
treatment (G, III), total number of white blood cells (WBC), red 
blood cells (RBC), platelets (PLT), hemoglobin (Hb)% and mean 
values of packed cell volume (PCV), mean corpuscular volume (MCV) 
and mean corpuscular hemoglobin (MCH) of experimental rats 
showed a significant increase as compared to the control group and 
the percentages of increase was 8.3%, 8.9%, 11.82%, 11.8%, 2.43%, 
2.68% and 0.57%, respectively. 
After combining treatment of cisplatin along with honey and royal 
jelly (G, IV), the total number of white blood cells (WBC), red blood 
cells (RBC), platelets (PLT), haemoglobin (Hb) % and mean values of 
packed cell volume (PCV), mean corpuscular volume (MCV) and 
mean corpuscular hemoglobin (MCH) of experimental rats was 
significantly increased as compared to animals treated with cisplatin 
(G, II). The percentage was 17.64%, 36.4%, 42.5%, 11.1%, 29.6 %, 
12.5.1%, 23.2%, respectively. 
 
Table 1: Haematological parameters of control and treated groups 
Parameter Groups 























































1.±indicate SD of three observations, 2. # (+) or (-) indicates percent variation over control, 3. w (+) or (-) indicates percent variation over cisplatin, 
4. Values are significant at *P<0.001, **P<0.01, ***P<0.05, 5. NS (Not significant), 6. a = P<0.001, **P<0.01, ***P<0.05 values compared with normal 
control, 7. b = P<0.001, **P<0.01, ***P<0.05 values compared with cisplatin group, 8. WBC = White blood cell, 9. RBC = Red blood cells, 10. PCV = 
Packed cell volume, 11. MCV = Mean corpuscular volume, 12. MCHC = Mean hemoglobin concentration. 
 
DISCUSSION 
In the present study it was observed that due to cisplatin treatment 
rats for 15 d, the total number of white blood cells (WBC), red blood 
cells (RBC), platelets (PLT), hemoglobin Hb%, and mean values of 
packed cell volume (PCV), mean corpuscular volume (MCV) and 
mean corpuscular hemoglobin (MCH) were significantly decreased. 
Similar results were reported by many authors [12-9].  
The results demonstrate that after 15 d of cisplatin treated rats, the 
total number of white blood cells (WBC) was significantly decreased. 
This might be due to infection and inflammation during cisplatin 
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treatment. The main molecular mechanism of cisplatin is 
myelotoxicity is due to its ability to bind with cellular DNA and 
render the cell incapable of replication [20]. Beside this, another 
mechanism of cisplatin is its ability to induce oxidative stress [21]. 
Reactive oxygen species are toxic to bone marrow cells and probably 
can trigger apoptosis and affect cell cycle, causing anemia and a 
decrease in leukocyte count [22]. Myelosuppression resulting in 
leukopenia and thrombocytopenia is a frequent and a major 
complication of cancer chemotherapy [23]. Many authors [24-8, 14-
5] observed that the number of WBC was decreased after exposure 
to cisplatin administration. 
After 15 d of cisplatin treatment to rats, the platelet count was 
significantly decreased compared to control group. This might be 
due to cisplatin inhibiting bone marrow activity or could be due to 
decreased production or increased consumption of platelets or due 
to the increased platelets aggregation [29]. Cisplatin causes oxidative 
stress in human platelets and lymphocytes, which might reflect on 
their life expectancy, the induction of apoptosis, and thereby 
ultimately reduced the number of these cells in the blood of 
experimental animals. However, the decrease in the WBCs number 
could be the consequence of infection and inflammation during 
cisplatin treatment and cisplatin metabolism in the experimental 
rats. [30]. Cisplatin reduced the platelet count in rats under 
experiment [25] and depleted the platelet number and caused 
cumulative anemia in rats [13].  
After 15 d of cisplatin treatment rats, the total number of RBC and 
Hb% were significantly decreased as compared to control. Similar 
results were reported by many authors [12-4, 16, 18, 25, 28]. The 
previous results suggested that there was an etiological relationship 
between anemia and cisplatin treatment. This relation could be 
explained through different mechanisms, including the destruction 
of bone marrow cells or increased osmotic fragility of RBC. Thus, 
cisplatin therapy might lead to anemia as a result of either 
suppression of the activity of hematopoietic tissues, impaired 
erythropoesis, and accelerated RBCs destruction because of the 
altered RBCs membrane permeability, increased RBCs mechanical 
fragility, and/or defective iron metabolism [13]. 
The reduction of RBC and Hb% attributed to the hemorrhage or 
hemolysis or because of impaired blood formation in bone marrow due 
to cisplatin toxicity and that led to imbalance between production and 
loss, inhibition of DNA synthesis in bone marrow precursor cells, 
leaving both RNA and protein synthesis intact and inhibition of many 
steps of heme biosynthesis in rats, as result of cisplatin use [31]. The 
reduction in the Hb% is related to suppression of erythropoiesis and 
iron supply to erythroblasts [32, 33].  
It also seems less likely that the reduced RBC count was a result of 
hematopoietic colony forming unit (CFU-E) maturation 
disturbances. Haemolyticanaemia has been reported in patients 
treated repeatedly with Cisplatin [34-6]. Antibodies reacting with 
Cisplatin-RBC-membrane complexes [34] can also cause hemolysis. 
It was also found that cisplatin therapy inhibited the production of 
renal erythropoietin, which resulted in a lower RBC production. The 
nephrotoxic effect of cisplatin showed a negative effect on 
erythropoiesis that resulted in the low production and the count of 
RBCs [12]. Cisplatin is said to cause anemia by interfering in the iron 
metabolism [37]. 
Due to cisplatin treatment rats for 15 d, mean values of packed cell 
volume (PCV), mean corpuscular volume (MCV) and mean 
corpuscular hemoglobin (MCH) values were significantly decreased 
as compared to control group. Similar results were reported by a 
number of authors [26, 16, 18]. 
Following the treatment with cisplatin, decreased MCV, MCH and 
reduced MCHC, suggest that a microcytic hypochromic anemia was due 
to the suppression of erythropoiesis [37]. It is reported that reactive 
oxygen species (ROS  ) increases hemoglobin glycation and erythrocyte 
fragility and bone marrow can be damaged by direct oxidation [38, 39]. 
More specifically haemoglobin-derived iron might contribute to the 
pathogenesis of cisplatin by inducing the oxidative stress [31, 40].  
Thus, in the present study, it was observed that the decrease in the 
MCV, MCH and MCHC after exposure to cisplatin was attributed to 
the production of erythrocytes with lower MCV, MCH and MCHC and 
these parameters closely related to Ht levels and Hb. Hb data could 
be strongly influenced by MCV, MCH and MCHC values [41].  
[42-3], it was found that cisplatin was more toxic to earlier 
haemopoietic progenitor cells than the mature ones. It was 
suggested that anemia could be due to the difference in time of 
maturation of the erythroid series. However, in a recent study [34] 
hemolysis was blamed for the production of anemia [44].  
The above-mentioned effects of cisplatin could be due to their ability 
to form free radicals [45]. This fact may ensure the hypothesis of the 
ability of cisplatin to form free radicals, which have been implicated 
as playing a role in the etiology of many alterations [46]. 
The success of a chemotherapy is dependent not only on effectively 
removing tumor cells but also on reducing the related 
immunosuppressive complications that are primarily caused by 
apoptosis of circulating leukocytes cells (leucopenia). Rat’s response 
to cisplatin chemotherapy caused severe immunosuppressive 
conditions, as reflected in a lower WBC count. 
In the present study it was observed that after honey and royal jelly 
treatment (G, III), the total number of white blood cells (WBC), red 
blood cells (RBC), hemoglobin % (Hb), platelets (PLT), and the mean 
values of packed cell volume (PCV), mean corpuscular volume (MCV) 
and mean corpuscular hemoglobin (MCH) of experimental rats were 
significantly increased as compared to control group. 
Antioxidants can prevent cell damage caused by the action of reactive 
oxygen species (ROS) and free radicals [47]. The antioxidant activities 
are related to a number of different mechanisms, such as free radical-
scavenging, hydrogen-donation, singlet oxygen quenching, metal ion 
chelation, and acting as a substrate for radicals such as superoxide and 
hydroxyl [48]. Recently, royal jelly has received particular attention as a 
highly efficient antioxidant and has the free radical scavenging capacity 
[49]. It contains many important compounds with biological activity 
such as free amino acids, proteins, sugars, fatty acids, minerals, and 
vitamins [50]. Honey is a natural antioxidant, which may contain 
flavonoids, ascorbic acid, tocopherols, catalase, and phenolic compounds 
all of which work together to provide a synergistic antioxidant effect, 
scavenging and eliminating free radicals [51-54]. 
In the present study it was observed that after combined treatment of 
cisplatin along with honey and royal jelly (G, IV), the total number of 
white blood cells (WBC), red blood cells (RBC), blood platelets (PLT), 
hemoglobin % (Hb) and mean values of packed cell volume (PCV), mean 
corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) of 
experimental rats were significantly increased as compared to animal 
treated with cisplatin (G, II). Honey and royal jelly have a protective role 
against many drugs, wherever [55] the honey protective effects on 
organs through the improvement in the hematological parameters 
(RBCs, WBCs and Platelets) because of decreased lipopolysaccharide in 
rats. Honey is reported to attenuate the hematological, effects induced by 
gentamicin [56, 45]. Natural honey significantly (P<0.05) restored Hb 
content, RBC, PCV, platelet and WBC close to control values in wistar 
albino rats fed hydrocarbon contaminated diets [57].  
The royal jelly has a hemato-curative role against azathioprine [17]. 
Honey has a hemato-curative role against zinc [58] and also it is 
reported that honey effects on amikacin-induced toxicity on 
hematological parameters [10]. 
The present study showed the improvement in the tested blood 
parameters as erythrocytes, hemoglobin, leukocytes, platelets and the 
mean value of packed cell volume (PCV), mean corpuscular volume 
(MCV) and mean corpuscular hemoglobin (MCH) indicates that 
honey and royal jelly administration prevented blood cell damage by 
maintaining the integrity of cells. Administration of royal jelly to rats 
ameliorated the effect of radiation that induced oxidative stress and 
hematological alterations [56].  
CONCLUSION 
Cisplatin caused a decrease in the total number of red blood cells 
(RBC), blood platelets (PLT), hemoglobin (HB) % and mean values of 
packed cell volume (PCV), mean corpuscular volume (MCV) and 
mean corpuscular hemoglobin (MCH), whereas honey and royal jelly 
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reversed these decreases. A high significant protective and curative 
effect on the studies on blood parameters due to honey and royal 
jelly indicates that honey and royal jelly should be supplemented to 
the patient when cisplatin chemotherapy is executed. 
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